Systemic inflammation a keyfactor in the pathogenesis of cardiovascular complications in
Systemic inflammation:a key factor in the pathogenesis of cardiovascular complications in obstructive sleep apnoea syndrome?
S Ryan,1,2C T Taylor,2W T McNicholas1,2
1Sleep Research Laboratory,St Vincent’s University Hospital, Dublin,Ireland;2School of Medicine and Medical Science, The Conway Institute,University College Dublin,Ireland Correspondence to: Professor W T McNicholas, Department of Respiratory Medicine,St Vincent’s University Hospital,Elm Park, Dublin4,Ireland;
walter.mcnicholas@ucd.ie This is a reprint of a paper that first appeared in Thorax,July 2009,volume64,pages631–6ABSTRACT
Obstructive sleep apnoea syndrome(OSAS)is a highly
prevalent disease and is recognised as a major public
health https://www.wendangku.net/doc/151251424.html,rge-scale epidemiological studies have
demonstrated an independent relationship between OSAS
and various cardiovascular disorders.The pathogenesis of
cardiovascular complications in OSAS is not completely
understood but a multifactorial aetiology is likely.
Inflammatory processes have emerged as critical in the
pathogenesis of atherosclerosis at all stages of atheroma
formation.Increased levels of various circulating markers
of inflammation including tumour necrosis factor a
(TNF a),interleukin6(IL6),IL-8and C-reactive protein
(CRP)have been reported as associated with future
cardiovascular risk.There is increasing evidence of
elevated inflammatory markers in OSAS with a significant
fall after effective treatment with continuous positive
airway pressure.This evidence is particularly strong for
TNF a,whereas studies on IL6and CRP have yielded
conflicting results possibly due to the confounding effects
of obesity.Cell culture and animal studies have
significantly contributed to our understanding of the
underlying mechanisms of the association between OSAS
and inflammation.Intermittent hypoxia,the hallmark of
OSAS,results in activation of pro-inflammatory tran-
scription factors such as nuclear factor kappa B(NF-k B)
and activator protein(AP)-1.These promote activation of
various inflammatory cells,particularly lymphocytes and
monocytes,with the downstream consequence of
expression of pro-inflammatory mediators that may lead
to endothelial dysfunction.This review provides a critical
analysis of the current evidence for an association
between OSAS,inflammation and cardiovascular disease,
discusses basic mechanisms that may be responsible for
this association and proposes future research possibilities.
Obstructive sleep apnoea syndrome(OSAS)is
characterised by instability of the upper airway
during sleep resulting in markedly reduced(hypop-
noea)or absent(apnoea)airflow at the nose/
mouth.These episodes are usually accompanied by
loud snoring and oxyhaemoglobin desaturation,
and are typically terminated by brief arousals
which result in marked sleep fragmentation and
diminished amounts of slow wave and rapid eye
movement(REM)sleep.1Patients with OSAS are
usually unaware of this sleep disruption,but the
changes in sleep architecture contribute signifi-
cantly to the prominent symptom of chronic
daytime sleepiness found in these patients.The
prevalence of OSAS among the adult population is
high,being4%in men and2%of women in the
Wisconsin Sleep Cohort Study.2Given the rapidly
rising incidence of obesity,which is the most
important risk factor of OSAS,the prevalence is
now likely to be significantly higher.3
The current management of moderate to severe
OSAS is largely dependent on nasal continuous
positive airway pressure(CPAP),which acts to
splint the upper airway open during sleep and thus
counteracts the negative suction pressure during
inspiration that promotes upper airway collapse in
these patients.45Nasal CPAP completely controls
the condition and has a dramatic effect on the
patient’s awake performance because of the
normalised sleep pattern.
OSAS is associated with significant morbidity
and mortality.The excessive daytime sleepiness
leads to impairments in quality of life,cognitive
performance and social functioning.6Furthermore,
the disorder is associated with a3–7-fold increase
in the rate of road traffic accidents.7The major
health burden in patients with OSAS,however,is
the strong risk of cardiovascular diseases such as
systemic arterial hypertension,coronary artery
disease,heart failure and stroke.8The association
between OSAS and cardiovascular diseases has
been suggested for many years and,more recently,
is corroborated by large-scale epidemiological and
prospective studies.The underlying mechanisms
mediating this association are incompletely under-
stood.Current evidence suggests that inflamma-
tory processes leading to endothelial dysfunction
play a pivotal role in the pathogenesis.
Following a brief summary of the current
epidemiological and clinical evidence of OSAS-
associated cardiovascular involvement and an over-
view of inflammatory processes in the athero-
sclerotic process,this article provides a critical
review of the current evidence of an association
between OSAS and systemic inflammation,
describes basic mechanisms that may be respon-
sible for this association and outlines future
research perspectives.
OSAS AND CARDIOVASCULAR DISEASES
An association between OSAS and the develop-
ment of cardiovascular diseases has been suggested
for several years.However,confounding variables
such as obesity,hypertension,smoking,alcohol
intake,age and level of exercise have made this
independent relationship difficult to prove.
Furthermore,many of the earlier studies on
OSAS and cardiovascular diseases used samples
from clinical populations which are usually not
representative of the condition in the general
population,and cannot be used to estimate the
Reprint review
public health impact of the disease.3However,the evidence of an association is growing,particularly with systemic arterial hypertension.Both the Sleep Heart Health Study which included over 6000subjects and the Wisconsin Sleep prospective cohort study involving 1069subjects have yielded convincing evidence of a modest but definite association,independent of possible confounding factors such as age,sex and obesity.910The prevalence of OSAS is particularly high in patients with drug-resistant hypertension;a recent study found occult OSAS in up to 83%of patients who had uncontrolled hypertension despite taking three or more antihypertensive agents at optimum doses.11
Data linking OSAS to other cardiovascular diseases are not as clear-cut but,nonetheless,supportive.The strongest evidence is provided by data from the Sleep Heart Health Study cohort which reports an independent association between OSAS and congestive cardiac failure,cerebrovascular disease and coronary artery disease.12In support,Peker et al followed patients with known coronary artery disease for 5years and observed a significantly higher mortality in patients with an apnoea/hypopnoea index (AHI)of >10/h in comparison with matched controls.13
A key question relates to the effect of CPAP therapy for OSAS on cardiovascular outcomes.Clearly,the ultimate answer to this question is still outstanding due to the lack of a long-term randomised trial.However,the withholding of effective CPAP therapy from patients with severe OSAS over a long period of time is unethical because of the recognised benefit of CPAP to daytime sleepiness and related symptoms in addition to the reduction in the risk of driving accidents.Three long-term cardiovascular outcome studies have compared patients on effective CPAP therapy with untreated or incompletely treated patients over 7–10years and consistently found a significantly increased mortality and morbidity in the untreated group.14–16However,patients intolerant of CPAP or unwilling to use the device do not represent a desirable control group as they may not be compliant with other medications.Randomised con-trolled studies looking at the effect of CPAP therapy on 24h blood pressure in general have yielded modest but significant reductions in blood pressure,both during the night and day,1718and the beneficial effects were greatest in patients with pre-existing hypertension.Furthermore,there is now good evidence suggesting a beneficial effect of CPAP on left ventricular function.Two recent randomised trials have shown significant improvements in left ventricular ejection fraction following
CPAP therapy for 1–3months in patients with systolic congestive cardiac failure and OSAS.1920
In summary,there is growing evidence of a causal link between OSAS and the development of cardiovascular diseases,and CPAP therapy potentially decreases cardiovascular morbid-ity and mortality.Given the high and steadily rising prevalence of OSAS,the clarification of its exact role as a cardiovascular risk factor is a major priority.Identification of the detailed mechanisms underlying cardiovascular disease in patients with OSAS will help to support the current epidemiological evidence.These mechanisms are,so far,still poorly understood.The pathogenesis is likely to be a multifactorial process involving a diverse range of mechanisms including sympathetic excitation,endothelial dysfunction and metabolic dysregulation (fig 1).8Current evidence suggests that inflammatory processes leading to endothelial dysfunction play a pivotal role in the pathogen-esis.Endothelial dysfunction substantially contributes to the development of various cardiovascular disease processes,parti-cularly atherosclerosis but also hypertension and congestive cardiac failure.
INFLAMMATION AND ATHEROSCLEROSIS
Over the last several years we have seen major developments in our understanding of the pathogenesis of atherosclerosis.Inflammatory mechanisms have emerged as playing a pivotal role in all stages of atherosclerotic plaque formation,from initiation of the fatty streak to the culmination in plaque rupture presenting as acute coronary syndrome.2122Systemic inflammation occurs in the vasculature as a response to injury,lipid peroxidation and perhaps infection.2324Resident or circulating leucocytes mediate the adherence of monocytes to the endothelium which in turn release a number of inflammatory mediators including cytokines such as tumour necrosis factor a (TNF a )or interleukin (IL)-1,chemokines such as IL-8or monocyte chemoattractant protein-1(MCP-1)and adhesion molecules such as intercellular adhesion mole-cule 1(ICAM-1)or selectins.Expression of adhesion molecules and chemokines facilitates the recruitment of macrophages,differentiated from monocytes,laden with oxidised lipid (foam cells).The accumulation of foam cells leads to the formation of a lipid pool,and collagen produced by smooth cells contributes to the strength of the fibrous cap.In particular,smooth cells also release IL6which is the main hepatic stimulus for the acute phase reactant,C-reactive protein (CRP),which causes expression of adhesion molecules and mediates MCP-1induction.25
EVIDENCE OF INFLAMMATION IN OSAS Circulating inflammatory markers in OSAS
The importance of inflammatory processes in the pathogenesis of cardiovascular diseases in OSAS is strongly supported by numerous studies demonstrating raised levels of circulating pro-inflammatory cytokines,chemokines and adhesion molecules in patients with OSAS in comparison with matched controls,and a significant fall with effective CPAP therapy.In particular,the potent pro-inflammatory cytokine TNF a has been evaluated by several case-control studies that have consistently shown raised levels in patients with OSAS compared with controls,indepen-dent of obesity,and a significant fall with effective CPAP therapy;both T cells and monocytes have been suggested as potential sources.26–30Recently,a large prospective study in men without cardiovascular diseases identified a strong association between OSAS severity and TNF a levels,independent
of
Figure 1Mechanisms associated with obstructive sleep apnoea syndrome (OSAS)contributing to cardiovascular diseases.
Reprint review
possible confounders such as body mass index(BMI),age or sleepiness.29Levels of the chemokine IL-8,which plays a key role in the process of adhesion of neutrophils and monocytes to the vascular endothelium,3132have also been shown to be raised in OSAS.2933Earlier studies have suggested increased IL6levels in patients with OSAS,263435but some of these reports may have been limited by smaller numbers,lack of adequately matched normal control populations,particularly in terms of BMI,and the inclusion of patients with established cardiovascular or metabolic diseases.Recent studies did not detect an association between OSAS and IL6.2936However,in a large cross-sectional analysis of the Cleveland Family Study there was an indepen-dent association between OSAS severity parameters and soluble IL6receptor,36which appears to be associated with the processes of inflammation and myocardial injury during the acute phase of acute myocardial infarction.37
A limited number of studies have also examined the levels of various cellular adhesion molecules such as intercellular adhe-sion molecule1(ICAM-1),vascular adhesion molecule1 (VCAM-1)and the family of selectins.The results consistently suggest an association between OSAS severity and circulating levels of cellular adhesion molecules,with one report also showing a significant fall after1month of effective CPAP therapy.38–42
Another potential link between OSAS and inflammation is the acute phase reactant C-reactive protein(CRP).In the high to normal range,when measured with a high-sensitivity assay, CRP levels are widely recognised as potent predictors of future cardiovascular events in apparently healthy subjects4344as well as in subjects with known cardiovascular disease.4546However, recent large-scale studies suggest that the elevated levels may,in fact,be attributable to the presence of abnormal conventional cardiovascular risk factors,particularly obesity.47–49The strong relationship between CRP levels and obesity has also influenced various studies investigating CRP levels in adults with OSAS, and therefore the role of CRP in OSAS is still under debate.This is reflected,for instance,in different conclusions obtained from two large cross-sectional studies in patients with OSAS.A study on316Japanese men detected a significant association between CRP and sleep-disordered breathing;however,the use of overnight oximetry as a screening tool for OSAS was a significant limitation.50On the other hand,the Wisconsin Sleep Cohort Study involving907adults failed to detect an independent association between CRP and OSAS after adjust-ment for BMI.51This discrepancy has also been evident in numerous case-control studies where some reports have identified increased levels of CRP in patients with OSAS3452–54 and others did not.55–57Furthermore,the impact of CPAP therapy on CRP levels is still unclear.3457–59In a recent randomised trial comparing therapeutic and subtherapeutic CPAP,effective OSAS treatment had no significant effect on levels of CRP or IL6.60
It is noteworthy that the role of increased inflammatory markers in the prediction of cardiovascular morbidity in OSAS is still unclear and long-term prospective studies on this subject are lacking.Furthermore,vascular inflammation leading to endothelial dysfunction may potentially occur and persist in the absence of a systemic inflammatory response.A recent study provides evidence of increased expression of the inflammatory markers inducible nitric oxide synthase(iNOS)and cyclo-oxygenase-2(COX-2)in harvested venous endothelial cells of patients with OSAS compared with matched controls,together with evidence of altered endothelial repair capacity that was reversed by CPAP therapy.61However,whether these alterations are associated with a detectable systemic inflammation is unknown.
Inflammatory cells and interactions with the endothelium in OSAS
Accumulation of leucocytes and their adhesion to the endothe-lium play a central role in the formation of atherosclerotic plaques.Activation of monocytes and T lymphocytes is among the crucial steps leading to the release of inflammatory mediators and adhesion molecules.
Activation of inflammatory cells and their interaction with endothelial cells have been demonstrated in OSAS.In a rat model,recurrent obstructive apnoeas led to a significant increase in various leucocyte-endothelial cell interactions such as leucocyte rolling and firm adhesion of leucocytes in comparison with a sham group.62Monocytes of patients with OSAS adhere more firmly to endothelial cells than those of control subjects,a process that is decreased by the application of CPAP therapy.63In the same study,OSAS was associated with the upregulation of the adhesion molecules CD15and CD11c in monocytes.Furthermore,in a cell culture model of repetitive hypoxia and reoxygenation,lipid uptake into macrophages and the expression of various adhesion molecules were significantly increased in comparison with control cells.64Further evidence is provided in the report by Minoguchi et al who demonstrated significantly higher spontaneous TNF a production by mono-cytes in patients with OSAS than in matched controls.30
T lymphocytes are also involved in the pathogenesis of atherosclerosis.In a series of experiments,Dyugovskaya et al showed that various subpopulations of cytotoxic T cells of patients with OSAS acquire an activated phenotype with the downstream consequence of increased cytotoxicity against endothelial cells.276566Furthermore,this activation process is associated with an increased intracellular content of the pro-inflammatory mediators TNF a and IL-8and a decrease of the anti-inflammatory cytokine IL-10.27
A recent in vitro study addressed the involvement of neutrophils in the cardiovascular pathogenesis of OSAS.67The results demonstrate impaired neutrophil apoptosis and increased adhesion molecule expression by these cells in OSAS,thus suggesting a further potential pathway in the atherosclerotic process.
MECHANISMS OF INFLAMMATORY PROCESSES IN OSAS
The basic mechanisms underlying the inflammatory process in OSAS remain unclear.In addition to sleep fragmentation and sleep deprivation,the unique form of hypoxia in OSAS—with repetitive short cycles of desaturation followed by rapid reoxygenation,termed intermittent hypoxia(IH)—is likely to play a significant role in the initiation of the inflammatory process.Various effects of IH on the cardiovascular system have been demonstrated using animal models.Rat and dog models of IH have consistently reported an increase in arterial blood pressure which is sustained even after cessation of the stimulus.6869Furthermore,enhanced sympathetic activity and decreased baroreflex sensitivity have been proposed to lead to the blood pressure increase in these models.70–72
There are various animal models supporting the development of atherosclerosis in response to IH.7374In mice on a high-cholesterol diet,IH led to the development of atherosclerotic lesions which was not observed in control animals that were not exposed to IH.73Furthermore,cardiovascular remodelling with altered adhesion molecule expression has been observed in
Reprint review
mice exposed to14days of IH.Interestingly,the right heart was not affected in this model whereas both the left ventricle and aorta demonstrated these changes.74
We recently showed in a cell culture model of IH a preferential activation of inflammatory pathways mediated by the transcription factor nuclear factor kappa B(NF-k B)over adaptive hypoxia-inducible factor1(HIF-1)-dependent path-ways,which contrasts with sustained hypoxia where activation of adaptive and protective pathways predominate.28NF-k B is a key player in inflammatory and innate immune responses and a master regulator of inflammatory gene expression,and genes such as TNF a or IL-8that are important to the atherosclerotic process and which have also been found upregulated in OSAS are under the control of this transcription factor.The central role of NF-k B in inflammatory processes in OSAS was furthermore suggested by increased activation in cardiovascular tissues in a mouse model of IH and also in cultured monocytes of patients with OSAS.7576The p38mitogen-activated protein kinase(MAPK)plays a major role in the process of IH-induced NF-k B activation,and pharmacological as well as targeted siRNA inhibition of p38leads to a significant reduction in NF-k B activity.77p38MAPK is a key player in inflammatory processes and is necessary for inflammatory cytokine produc-tion and signalling.78Furthermore,p38is activated in response to environmental stresses and is critically involved in the pathophysiology of a variety of cardiovascular diseases.79–84 Activation of p38MAPK was also demonstrated in a rat model of IH which was associated with delayed cardioprotection against prolonged ischaemia.85
Although our cell culture model demonstrates preferential activation of inflammatory over adaptive pathways by IH,28 more prolonged exposure to IH may activate HIF-1,and this finding has been reported in another cell culture model86and in a mouse model of IH.87In particular,Yuan and co-workers reported increased HIF-1transcriptional activity in response to 60and120cycles of IH but not with fewer cycles.86
IH also activates other inflammatory transcription factors. Among them is the activator protein complex-1(AP-1),formed by the proteins c-Fos and c-Jun.AP-1drives transcriptional activation of a variety of genes including tyrosine hydroxylase which encodes the key enzyme in catecholamine synthesis.88c-Fos upregulation by IH has been demonstrated in an animal as well as in a cell culture model.8689In a rat model,activation of inflammatory pathways by IH was associated with an impair-ment of neurocognitive function,a process which was reversed once the stimulus was removed.90
Yet to be determined remain(s)the initial sensing and signalling event(s)which occur(s)in response to IH.It has been proposed that repetitive episodes of hypoxia—and particularly of reoxygenation—lead to an increased production of reactive oxygen species(ROS).91In support of this proposal,increased circulating levels of markers of oxidative stress have been found in patients with OSAS,and in vitro studies have demonstrated increased ROS production from leucocytes of patients with OSAS which was reversed by CPAP therapy.63However,the involvement of ROS in NF-k B signalling is controversial,and experiments by Hayakawa et al indicate that NF-k B is unlikely to be a sensor of oxidative stress and previous results may have been influenced by cell type dependency and methodological limitations.92In support of this,we did not detect an influence of the ROS scavenger N-acetyl-L-cysteine on NF-k B activation by IH in our cell culture model(unpublished data). Collectively,the available evidence indicates that activation of inflammatory transcription factors,particularly NF-k B,by IH is critical in the pathogenesis of atherosclerosis in patients with OSAS.
INTERACTION WITH OBESITY
It is important to distinguish the inflammatory responses directly related to OSAS from obesity-related inflammation. Obesity,particularly visceral adiposity,is associated with chronic low-grade inflammation,as indicated by increased levels of the inflammatory markers CRP and IL6in the circulation of obese subjects.93Adipose tissue produces and releases a variety of pro-inflammatory and anti-inflammatory factors,including the adipokines leptin,adiponectin and resistin,as well as cytokines and chemokines such as IL6, TNF a,monocyte chemoattractant protein1(MCP-1)and others.These molecules produced by adipose tissue have been implicated as active participants in the development of insulin resistance and cardiovascular diseases.94Thus,both obesity and OSAS are pro-inflammatory conditions and may mutually enhance the progression and severity of cardiovascular diseases. FUTURE RESEARCH PERSPECTIVE
While substantial progress has been made in the identification of inflammatory processes in the cardiovascular pathogenesis of OSAS,a significant number of questions remain unanswered. The impact of CPAP therapy on cardiovascular diseases in OSAS has not been fully investigated,but may prove difficult to answer as a long-term randomised trial faces ethical problems. Understanding the basic molecular mechanisms of cardiovas-cular complications in OSAS can help to fill the gap of missing epidemiological evidence and,therefore,research in this field should be a major priority.Few translational studies have been undertaken so far that have explored basic mechanisms
of Figure2Selective activation of inflammatory pathways by intermittent hypoxia.Intermittent hypoxia leads to a preferential activation of nuclear factor kappa B(NF-k B)-dependent inflammatory pathways over adaptive hypoxia-inducible factor1(HIF-1)mediated pathways.This results in the production of various pro-inflammatory mediators which,in turn, mediates the interaction of inflammatory and endothelial cells resulting in endothelial dysfunction.ICAM-1,intercellular adhesion molecule1; IL,interleukin;OSAS,obstructive sleep apnoea syndrome;TNF a,tumour necrosis factor a;VCAM-1,vascular adhesion molecule1.
Reprint review
cardiovascular diseases in OSAS with application of the findings to the clinical setting.Many of the clinical studies looking at inflammatory markers in OSAS have been influenced by small numbers,inadequately matched populations(particularly for BMI)and inclusion of patients with established cardiovascular or metabolic diseases.It is thus not surprising that conflicting results have been reported.
There is therefore a clear need for large-scale multicentre studies of carefully defined patient and control populations. Such studies carry the prospect of evaluating potential interac-tions between different basic mechanisms and cardiovascular disease and providing potential treatment options.As this review outlines,the basic inflammatory mechanisms underlying cardiovascular complications in OSAS are complex.There is emerging evidence that IH plays a central role in the initiation of the inflammatory processes,but additional studies involving cell,animal and human models are required to adequately explore the mechanisms involved.
CONCLUSIONS
Inflammatory processes are rapidly emerging as playing a central role in the cardiovascular pathogenesis of OSAS.The repetitive cycles of short periods of hypoxia followed by rapid reoxygenation preferentially activate inflammatory—particu-larly NF-k B-mediated—pathways.These mechanisms result in activation of inflammatory cells,release of inflammatory mediators and associated vascular pathophysiology(fig2). Future therapeutic approaches to ameliorating the cardiovas-cular risk factors associated with OSAS should take into account the possibility of inhibiting systemic inflammatory processes.
Funding:Health Research Board(Ireland),Science Foundation of Ireland,Wellcome Trust
Competing interests:None.
REFERENCES
1.Guilleminault C,Tilkian A,Dement WC.The sleep apnea syndromes.Annu Rev Med
1976;27:465–84.
2.Young T,Palta M,Dempsey J,et al.The occurrence of sleep-disordered breathing
among middle-aged adults.N Engl J Med1993;328:1230–5.
3.Young T,Peppard PE,Gottlieb DJ.Epidemiology of obstructive sleep apnea:a
population health perspective.Am J Respir Crit Care Med2002;165:1217–39.
4.Deegan PC,McNicholas WT.Pathophysiology of obstructive sleep apnoea.Eur
Respir J1995;8:1161–78.
5.Sullivan CE,Issa FG,Berthon-Jones M,et al.Reversal of obstructive sleep apnoea
by continuous positive airway pressure applied through the https://www.wendangku.net/doc/151251424.html,ncet
1981;1:862–5.
6.Engleman HM,Douglas NJ.Sleep.4:Sleepiness,cognitive function,and quality of
life in obstructive sleep apnoea/hypopnoea syndrome.Thorax2004;59:618–22. 7.Stoohs RA,Bingham LA,Itoi A,et al.Sleep and sleep-disordered breathing in
commercial long-haul truck drivers.Chest1995;107:1275–82.
8.McNicholas WT,Bonsigore MR.Sleep apnoea as an independent risk factor for
cardiovascular disease:current evidence,basic mechanisms and research priorities.
Eur Respir J2007;29:156–78.
9.Nieto FJ,Young TB,Lind BK,et al.Association of sleep-disordered breathing,sleep
apnea,and hypertension in a large community-based study.Sleep Heart Health
Study.JAMA2000;283:1829–36.
10.Peppard PE,Young T,Palta M,et al.Prospective study of the association between
sleep-disordered breathing and hypertension.N Engl J Med2000;342:1378–84. 11.Logan AG,Perlikowski SM,Mente A,et al.High prevalence of unrecognized sleep
apnoea in drug-resistant hypertension.J Hypertens2001;19:2271–7.
12.Shahar E,Whitney CW,Redline S,et al.Sleep-disordered breathing and
cardiovascular disease:cross-sectional results of the Sleep Heart Health Study.
Am J Respir Crit Care Med2001;163:19–25.
13.Peker Y,Hedner J,Kraiczi H,et al.Respiratory disturbance index:an independent
predictor of mortality in coronary artery disease.Am J Respir Crit Care Med
2000;162:81–6.
14.Peker Y,Hedner J,Norum J,et al.Increased incidence of cardiovascular disease in
middle-aged men with obstructive sleep apnea:a7-year follow-up.Am J Respir Crit Care Med2002;166:159–65.15.Marin JM,Carrizo SJ,Vicente E,et al.Long-term cardiovascular outcomes in men
with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure:an observational https://www.wendangku.net/doc/151251424.html,ncet2005;365:1046–53.
16.Doherty LS,Kiely JL,Swan V,et al.Long-term effects of nasal continuous positive
airway pressure therapy on cardiovascular outcomes in sleep apnea syndrome.Chest 2005;127:2076–84.
17.Becker HF,Jerrentrup A,Ploch T,et al.Effect of nasal continuous positive airway
pressure treatment on blood pressure in patients with obstructive sleep apnea.
Circulation2003;107:68–73.
18.Pepperell JC,Ramdassingh-Dow S,Crosthwaite N,et al.Ambulatory blood
pressure after therapeutic and subtherapeutic nasal continuous positive airway
pressure for obstructive sleep apnoea:a randomised parallel https://www.wendangku.net/doc/151251424.html,ncet
2002;359:204–10.
19.Mansfield DR,Gollogly NC,Kaye DM,et al.Controlled trial of continuous positive
airway pressure in obstructive sleep apnea and heart failure.Am J Respir Crit Care Med2004;169:361–6.
20.Kaneko Y,Floras JS,Usui K,et al.Cardiovascular effects of continuous positive
airway pressure in patients with heart failure and obstructive sleep apnea.
N Engl J Med2003;348:1233–41.
21.Ross R.Atherosclerosis:an inflammatory disease.N Engl J Med1999;340:115–26.
22.Libby P.Inflammation in atherosclerosis.Nature2002;420:868–74.
23.Glass CK,Witztum JL.Atherosclerosis.the road ahead.Cell2001;104:503–16.
24.Lusis AJ.Atherosclerosis.Nature2000;407:233–41.
25.Pasceri V,Willerson JT,Yeh ET.Direct proinflammatory effect of C-reactive protein
on human endothelial cells.Circulation2000;102:2165–8.
26.Ciftci TU,Kokturk O,Bukan N,et al.The relationship between serum cytokine levels
with obesity and obstructive sleep apnea syndrome.Cytokine2004;28:87–91. 27.Dyugovskaya L,Lavie P,Lavie L.Phenotypic and functional characterization of blood
gammadelta T cells in sleep apnea.Am J Respir Crit Care Med2003;168:242–9.
28.Ryan S,Taylor CT,McNicholas WT.Selective activation of inflammatory pathways
by intermittent hypoxia in obstructive sleep apnea syndrome.Circulation
2005;112:2660–7.
29.Ryan S,Taylor CT,McNicholas WT.Predictors of elevated nuclear factor-kappaB-
dependent genes in obstructive sleep apnea syndrome.Am J Respir Crit Care Med 2006;174:824–30.
30.Minoguchi K,Tazaki T,Yokoe T,et al.Elevated production of tumor necrosis factor-
alpha by monocytes in patients with obstructive sleep apnea syndrome.Chest
2004;126:1473–9.
31.Gerszten RE,Garcia-Zepeda EA,Lim YC,et al.MCP-1and IL-8trigger firm adhesion of
monocytes to vascular endothelium under flow conditions.Nature1999;398:718–23.
32.Aukrust P,Yndestad A,Smith C,et al.Chemokines in cardiovascular risk prediction.
Thromb Haemost2007;97:748–54.
33.Ohga E,Tomita T,Wada H,et al.Effects of obstructive sleep apnea on circulating
ICAM-1,IL-8,and MCP-1.J Appl Physiol2003;94:179–84.
34.Yokoe T,Minoguchi K,Matsuo H,et al.Elevated levels of C-reactive protein and
interleukin-6in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure.Circulation2003;107:1129–34.
35.Vgontzas AN,Papanicolaou DA,Bixler EO,et al.Elevation of plasma cytokines in
disorders of excessive daytime sleepiness:role of sleep disturbance and obesity.
J Clin Endocrinol Metab1997;82:1313–6.
36.Mehra R,Storfer-Isser A,Kirchner HL,et al.Soluble interleukin6receptor:a novel
marker of moderate to severe sleep-related breathing disorder.Arch Intern Med
2006;166:1725–31.
37.Ueda K,Takahashi M,Ozawa K,et al.Decreased soluble interleukin-6receptor in
patients with acute myocardial infarction.Am Heart J1999;138:908–15.
38.Ohga E,Nagase T,Tomita T,et al.Increased levels of circulating ICAM-1,VCAM-1,
and L-selectin in obstructive sleep apnea syndrome.J Appl Physiol1999;87:10–4.
39.El-Solh AA,Mador MJ,Sikka P,et al.Adhesion molecules in patients with coronary
artery disease and moderate-to-severe obstructive sleep apnea.Chest
2002;121:1541–7.
40.Ursavas A,Karadag M,Rodoplu E,et al.Circulating ICAM-1and VCAM-1levels in
patients with obstructive sleep apnea syndrome.Respiration2007;74:525–32. 41.Zamarron-Sanz C,Ricoy-Galbaldon J,Gude-Sampedro F,et al.Plasma levels of
vascular endothelial markers in obstructive sleep apnea.Arch Med Res2006;37:552–5.
42.Chin K,Nakamura T,Shimizu K,et al.Effects of nasal continuous positive airway
pressure on soluble cell adhesion molecules in patients with obstructive sleep apnea syndrome.Am J Med2000;109:562–7.
43.Ridker PM,Cushman M,Stampfer MJ,et al.Inflammation,aspirin,and the risk of
cardiovascular disease in apparently healthy men.N Engl J Med1997;336:973–9.
44.Koenig W,Sund M,Frohlich M,et al.C-Reactive protein,a sensitive marker of
inflammation,predicts future risk of coronary heart disease in initially healthy middle-aged men:results from the MONICA(Monitoring Trends and Determinants in
Cardiovascular Disease)Augsburg Cohort Study,1984to1992.Circulation
1999;99:237–42.
45.Heeschen C,Hamm CW,Bruemmer J,et al.Predictive value of C-reactive protein
and troponin T in patients with unstable angina:a comparative analysis.CAPTURE Investigators.Chimeric c7E3AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial.J Am Coll Cardiol2000;35:1535–42.
46.Haverkate F,Thompson SG,Pyke SD,et al.Production of C-reactive protein and risk
of coronary events in stable and unstable angina.European Concerted Action on
Thrombosis and Disabilities Angina Pectoris Study https://www.wendangku.net/doc/151251424.html,ncet1997;349:462–6.
Reprint review
https://www.wendangku.net/doc/151251424.html,ler M,Zhan M,Havas S.High attributable risk of elevated C-reactive protein level
to conventional coronary heart disease risk factors:the Third National Health and Nutrition Examination Survey.Arch Intern Med2005;165:2063–8.
48.Khera A,de Lemos JA,Peshock RM,et al.Relationship between C-reactive protein
and subclinical atherosclerosis:the Dallas Heart Study.Circulation2006;113:38–43.
49.Cao JJ,Arnold AM,Manolio TA,et al.Association of carotid artery intima-media
thickness,plaques,and C-reactive protein with future cardiovascular disease and all-cause mortality:the Cardiovascular Health Study.Circulation2007;116:32–8. 50.Yao M,Tachibana N,Okura M,et al.The relationship between sleep-disordered
breathing and high-sensitivity C-reactive protein in Japanese men.Sleep
2006;29:661–5.
51.Taheri S,Austin D,Lin L,et al.Correlates of serum C-reactive protein(CRP):no
association with sleep duration or sleep disordered breathing.Sleep2007;30:991–6.
52.Kokturk O,Ciftci TU,Mollarecep E,et al.Elevated C-reactive protein levels and
increased cardiovascular risk in patients with obstructive sleep apnea syndrome.Int Heart J2005;46:801–9.
53.Shamsuzzaman AS,Winnicki M,Lanfranchi P,et al.Elevated C-reactive protein in
patients with obstructive sleep apnea.Circulation2002;105:2462–4.
54.Can M,Acikgoz S,Mungan G,et al.Serum cardiovascular risk factors in obstructive
sleep apnea.Chest2006;129:233–7.
55.Barcelo A,Barbe F,Llompart E,et al.Effects of obesity on C-reactive protein level
and metabolic disturbances in male patients with obstructive sleep apnea.Am J Med 2004;117:118–21.
56.Guilleminault C,Kirisoglu C,Ohayon MM.C-reactive protein and sleep-disordered
breathing.Sleep2004;27:1507–11.
57.Ryan S,Nolan GM,Hannigan E,et al.Cardiovascular risk markers in obstructive sleep
apnoea syndrome and correlation with obesity.Thorax2007;62:509–14.
58.Akashiba T,Akahoshi T,Kawahara S,et al.Effects of long-term nasal continuous
positive airway pressure on C-reactive protein in patients with obstructive sleep
apnea syndrome.Intern Med2005;44:899–900.
59.Steiropoulos P,Tsara V,Nena E,et al.Effect of continuous positive airway pressure
treatment on serum cardiovascular risk factors in patients with obstructive sleep
apnea-hypopnea syndrome.Chest2007;132:843–51.
60.Kohler MM,Ayers L,Pepperell JCMF,et al.Effects of continuous positive airway
pressure on systemic inflammation in patients with moderate to severe obstructive sleep apnoea:a randomised controlled trial.Thorax2009;64:67–73.
61.Jelic S,Padeletti M,Kawut SM,et al.Inflammation,oxidative stress,and repair
capacity of the vascular endothelium in obstructive sleep apnea.Circulation
2008;117:2270–8.
62.Nacher M,Serrano-Mollar A,Farre R,et al.Recurrent obstructive apneas trigger
early systemic inflammation in a rat model of sleep apnea.Respir Physiol Neurobiol 2007;155:93–6.
63.Dyugovskaya L,Lavie P,Lavie L.Increased adhesion molecules expression and
production of reactive oxygen species in leukocytes of sleep apnea patients.
Am J Respir Crit Care Med2002;165:934–9.
https://www.wendangku.net/doc/151251424.html,ttimore JD,Wilcox I,Nakhla S,et al.Repetitive hypoxia increases lipid loading in
human macrophages:a potentially atherogenic effect.Atherosclerosis
2005;179:255–9.
65.Dyugovskaya L,Lavie P,Lavie L.Lymphocyte activation as a possible measure of
atherosclerotic risk in patients with sleep apnea.Ann N Y Acad Sci2005;1051:340–50.
66.Dyugovskaya L,Lavie P,Hirsh M,et al.Activated CD8+T-lymphocytes in
obstructive sleep apnoea.Eur Respir J2005;25:820–8.
67.Dyugovskaya L,Polyakov A,Lavie P,et al.Delayed neutrophil apoptosis in sleep
apnea patients.Am J Respir Crit Care Med2008;177:544–54.
68.Brooks D,Horner RL,Kozar LF,et al.Obstructive sleep apnea as a cause of systemic
hypertension.Evidence from a canine model.J Clin Invest1997;99:106–9.
69.Fletcher EC,Lesske J,Qian W,et al.Repetitive,episodic hypoxia causes diurnal
elevation of blood pressure in rats.Hypertension1992;19:555–61.
70.Fletcher EC,Lesske J,Culman J,et al.Sympathetic denervation blocks blood
pressure elevation in episodic hypoxia.Hypertension1992;20:612–9.71.Bao G,Metreveli N,Li R,et al.Blood pressure response to chronic episodic hypoxia:
role of the sympathetic nervous system.J Appl Physiol1997;83:95–101.
https://www.wendangku.net/doc/151251424.html,i CJ,Yang CC,Hsu YY,et al.Enhanced sympathetic outflow and decreased
baroreflex sensitivity are associated with intermittent hypoxia-induced systemic
hypertension in conscious rats.J Appl Physiol2006;100:1974–82.
73.Savransky V,Nanayakkara A,Li J,et al.Chronic intermittent hypoxia induces
atherosclerosis.Am J Respir Crit Care Med2007;175:1290–7.
74.Dematteis M,Julien C,Guillermet C,et al.Intermittent hypoxia induces early
functional cardiovascular remodeling in mice.Am J Respir Crit Care Med
2008;177:227–35.
75.Greenberg H,Ye X,Wilson D,et al.Chronic intermittent hypoxia activates nuclear
factor-kappaB in cardiovascular tissues in vivo.Biochem Biophys Res Commun
2006;343:591–6.
76.Yamauchi M,Tamaki S,Tomoda K,et al.Evidence for activation of nuclear factor
kappaB in obstructive sleep apnea.Sleep Breath2006;10:189–93.
77.Ryan S,McNicholas WT,Taylor CT.A critical role for p38map kinase in NF-kappaB
signaling during intermittent hypoxia/reoxygenation.Biochem Biophys Res Commun 2007;355:728–33.
78.Kotlyarov A,Neininger A,Schubert C,et al.MAPKAP kinase2is essential for LPS-
induced TNF-alpha biosynthesis.Nat Cell Biol1999;1:94–7.
79.Behr TM,Nerurkar SS,Nelson AH,et al.Hypertensive end-organ damage and
premature mortality are p38mitogen-activated protein kinase-dependent in a rat
model of cardiac hypertrophy and dysfunction.Circulation2001;104:1292–8.
80.Cain BS,Meldrum DR,Meng X,et al.p38MAPK inhibition decreases TNF-alpha
production and enhances postischemic human myocardial function.J Surg Res
1999;83:7–12.
81.Cook SA,Sugden PH,Clerk A.Activation of c-Jun N-terminal kinases and p38-
mitogen-activated protein kinases in human heart failure secondary to ischaemic
heart disease.J Mol Cell Cardiol1999;31:1429–34.
82.Li M,Georgakopoulos D,Lu G,et al.p38MAP kinase mediates inflammatory cytokine
induction in cardiomyocytes and extracellular matrix remodeling in heart.Circulation 2005;111:2494–502.
83.Liao P,Wang SQ,Wang S,et al.p38Mitogen-activated protein kinase mediates a
negative inotropic effect in cardiac myocytes.Circ Res2002;90:190–6.
84.Zarubin T,Han J.Activation and signaling of the p38MAP kinase pathway.Cell Res
2005;15:11–8.
85.Beguin PC,Belaidi E,Godin-Ribuot D,et al.Intermittent hypoxia-induced delayed
cardioprotection is mediated by PKC and triggered by p38MAP kinase and Erk1/2.
J Mol Cell Cardiol2007;42:343–51.
86.Yuan G,Nanduri J,Bhasker CR,et al.Ca2+/calmodulin kinase-dependent activation
of hypoxia inducible factor1transcriptional activity in cells subjected to intermittent hypoxia.J Biol Chem2005;280:4321–8.
87.Peng YJ,Yuan G,Ramakrishnan D,et al.Heterozygous HIF-1alpha deficiency impairs
carotid body-mediated systemic responses and reactive oxygen species generation in mice exposed to intermittent hypoxia.J Physiol2006;577:705–16.
88.Shaulian E,Karin M.AP-1as a regulator of cell life and death.Nat Cell Biol
2002;4:E131–6.
89.Greenberg HE,Sica AL,Scharf SM,et al.Expression of c-fos in the rat brainstem
after chronic intermittent hypoxia.Brain Res1999;816:638–45.
90.Goldbart A,Row BW,Kheirandish L,et al.Intermittent hypoxic exposure during light
phase induces changes in cAMP response element binding protein activity in the rat CA1hippocampal region:water maze performance correlates.Neuroscience
2003;122:585–90.
https://www.wendangku.net/doc/151251424.html,vie L.Obstructive sleep apnoea syndrome:an oxidative stress disorder.Sleep
Med Rev2003;7:35–51.
92.Hayakawa M,Miyashita H,Sakamoto I,et al.Evidence that reactive oxygen species
do not mediate NF-kappaB activation.Embo J2003;22:3356–66.
93.Alam I,Lewis K,Stephens JW,et al.Obesity,metabolic syndrome and sleep
apnoea:all pro-inflammatory states.Obes Rev2007;8:119–27.
94.Fantuzzi G.Adipose tissue,adipokines,and inflammation.J Allergy Clin Immunol
2005;115:911–20.
Reprint review